Company intelligence / Profile preview

Alzomar

Framingham, Massachusetts, United Statesalzomar.com ↗

Ownership: Private
Development stage: Other

Overview

Alzheon is a clinical-stage biopharmaceutical company developing valiltramiprosate (ALZ-801), an oral small molecule anti-amyloid treatment for early symptomatic Alzheimer’s disease. The company focuses on patients with the highest genetic risk—APOE4/4 homozygotes—and has completed a pivotal Phase 3 study. Earlier open-label biomarker studies support its potential as a disease-modifying therapy. Regulatory submission preparations are underway pending final data readout in 2025.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

BELLUS Health – exclusive license for ALZ‑801 and related compounds/platform; BELLUS receives royalties and milestone payments.National Institute on Aging – $51M grant funding to support clinical trials.

Beyond the preview

Go deeper on Alzomar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzomar.

Explore the full profile